Details
Category: Volume 08 Issue 06 June 2020
Hits: 1217

Title: Coagulation in the Prognosis of Severe COVID-19

Authors: Kallem Sharat Venkat Reddy, Aakunuri Akhil

 DOI: https://dx.doi.org/10.18535/jmscr/v8i6.97

Abstract

A relatively high mortality rate of patients with Corona virus disease 2019 is worrying, with hospitals worldwide continuing to admit flood of patients with corona virus disease, the confusing pathogenesis behind this severe mortality rate is slowly being understood. Respiratory involvement in the progression is already known; new inputs show a possible cardiac system involvement with potential involvement of coagulopathy in COVID-19. To be specific disseminated intravascular coagulation (DIC) with high risk of venous thromboembolism. Severity in COVID-19 patients is shown directly related with coagulation in the patients. Also from an analysis in patients in Wuhan-China,it is reported that heparin treatment reduced mortality rate in patients with severe COVID-19. In this article we describe the potential coagulation features of patients with corona virus disease.

Keywords: COVID-19, Corona virus, disseminated intravascular coagulation (DIC), Anticoagulants, Venous thromboembolism, D-dimer.

References

  1. Porfidia, A., & Pola, R. (2020). Venous thromboembolism in COVID‐19 patients. Journal of Thrombosis and Haemostasis.
  2. Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 18(4), 844-847.
  3. Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, The Journal of the American Society of Hematology, 135(23), 2033-2040.
  4. Disseminated intravascular coagulation (DIC),National Heart, Lung, and Blood Institute https://www.nhlbi.nih.gov/health-topics/disseminated-intravascular-coagulation
  5. https://www.worldthrombosisday.org/issue/vte/#:~:text=Venous%20thromboembolism%20(VTE)%20is%20a,as%20pulmonary%20embolism%2C%20PE).
  6. Adam, S. S., Key, N. S., & Greenberg, C. S. (2009). D-dimer antigen: current concepts and future prospects. Blood, The Journal of the American Society of Hematology, 113(13), 2878-2887.
  7. Li, T., Lu, H., & Zhang, W. (2020). Clinical observation and management of COVID-19 patients. Emerging microbes & infections, 9(1), 687-690.
  8. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, Zhou-P
  9. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity.Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, Li L, He R, Tan Y, Deng X, Gao M, Tang G, Zhao L, Wang J, Fan Q, Wen C, Tong Y, Tang Y, Hu F, Li F, Tang X.Emerg Microbes Infect. 2020; 9(1):469-473.
  10. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.Lin L, Lu L, Cao W, Li TEmerg Microbes Infect. 2020 Dec; 9(1):727-732.
  11. Li, T. (2020). Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2. 0) working group of 2019 novel coronavirus, Peking union medical college hospital. Emerging microbes & infections, 9(1), 582-585.
  12. Atallah, B., Mallah, S. I., & AlMahmeed, W. (2020). Anticoagulation in COVID-19. European Heart Journal—Cardiovascular Pharmacotherapy.
  13. Kollias, A., Kyriakoulis, K. G., Dimakakos, E., Poulakou, G., Stergiou, G. S., & Syrigos, K. (2020). Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action. British journal of haematology.
  14. Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis, 18(5), 1094-1099.
  15. Klok, F. A., Kruip, M. J. H. A., Van Der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., ... & Endeman, H. (2020). Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thrombosis Research.)
  16. Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., ... & Fafi-Kremer, S. (2020). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive care medicine, 1-10.
  17. Llitjos, J. F., Leclerc, M., Chochois, C., Monsallier, J. M., Ramakers, M., Auvray, M., & Merouani, K. (2020). High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. Journal of Thrombosis and Haemostasis.
  18. Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 18(4), 844-847
  19. Cui, S., Chen, S., Li, X., Liu, S., & Wang, F. (2020). Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis.
  20. Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 18(4), 844-847.
  21. Salim Rezaie(2020) COVID-19:Thrombosis and Hemoglobin.
    https://rebelem.com/covid-19-thrombosis-and-hemoglobin/

Corresponding Author

Aakunuri Akhil

Pharm-D, Bharat Institute of Technology, Hyderabad, Telangana-500072